; table of contents. Sec. 2. Coverage of testing for COVID–19. Sec. 3. Waiving cost sharing under the Medicare program for certain visits relating to testing for COVID–19. Sec. 4. Coverage of testing for COVID–19 at no cost sharing under the Medicare Advantage program. Sec. 5. Coverage at no cost sharing of COVID–19 testing under Medicaid and CHIP. Sec. 6. Laboratory reimbursement for diagnostic testing for COVID–19 in uninsured individuals. Sec. 7. Application with respect to TRICARE, coverage for veterans, and coverage for Federal civilians. Sec. 8. Coverage of testing for COVID–19 at no cost sharing for Indians receiving contract health services. 2. Coverage of testing for COVID–19 (a) In general A group health plan and a health insurance issuer offering group or individual health insurance coverage (including a grandfathered health plan (as defined in section 1251(e) of the Patient Protection and Affordable Care Act)) shall provide coverage, and shall not impose any cost sharing (including deductibles, copayments, and coinsurance) requirements or prior authorization or other medical management requirements, for the following items and services furnished during any portion of the emergency period defined in paragraph (1)(B) of section 1135(g) of the Social Security Act ( 42 U.S.C. 1320b–5(g) ) beginning on or after the date of the enactment of this Act: (1) In vitro diagnostic products (as defined in section 809.3(a) of title 21, Code of Federal Regulations) for the detection of SARS–CoV–2 or the diagnosis of the virus that causes COVID–19 that are approved, cleared, or authorized under section 510(k), 513, 515, or 564 of the Federal Food, Drug, and Cosmetic Act, and the administration of such in vitro diagnostic products. (2) Health care provider office visits, urgent care center visits, and emergency room visits that result in an order for or administration of an in vitro diagnostic product described in paragraph (1). (b) Enforcement The provisions of subsection (a) shall be applied by the Secretary of